Background -Non-steroidal antiinflammatory drugs (NSAIDs) are used to assess the role of prostaglandins in asthma but their effects on bronchoconstrictor challenges have been inconsistent. The effects of three nebulised nonsteroidal anti-inflammatory drugs on the airway response to inhaled sodium metabisulphite (MBS) and adenosine 5'-monophosphate (AMP) were compared in the same asthmatic subjects to see whether contractile prostaglandins were involved in MBS or AMP induced bronchoconstriction. A possible protective effect of the osmolarity or pH of the inhaled solutions was also assessed. Methods -Two double blind placebo controlled studies were carried out. In study 1, 15 non-aspirin sensitive patients with mild asthma attended on four occasions and inhaled 5 ml of lysine aspirin (Laspirin) 900 mg, indomethacin 50 mg, sodium salicylate 800 mg, or saline 20 minutes before an inhaled MBS challenge.
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On four further occasions 14 of the patients inhaled the same solutions followed by an inhaled AMP challenge. In study 2, 10 of the patients attended on four additional occasions and inhaled 5 ml of 0.9%, 3%, 10%, or 9.5% saline with indomethacin 50 mg 20 minutes before an inhaled MBS challenge. Results -In study 1 inhaled lysine aspirin had a similar effect on MBS and AMP induced bronchoconstriction, increasing the provocative dose causing a 20% fall in FEV1 (PD20) by 1.29 (95% CI 0.54 to 2.03) and 1.23 (95% CI 0.53 to 1.93) doubling doses, respectively. Indomethacin increased the MBS PD20 and AMP PD20 by 0.64 (95% CI -0.1 to 1.38) and 0.99 (95% CI 0.29 to 1.69) doubling doses, respectively. Sodium salicylate had no significant effect on either challenge. The two solutions causing most inhibition were the most acidic and the most alkaline. In study 2 inhaled 9.5% saline with indomethacin (osmolarity 3005 mOsm/kg) increased the MBS PD20 by 1 The cyclooxygenase products of arachidonic acidmetabolism include several potentbronchoactive prostaglandins (PGs) and thromboxane. Inhaled PGF2Q and PGD2 cause bronchoconstriction in patients with asthma' whereas PGE2 protects against challenges that act indirectly on the airways including sodium metabisulphite,' exercise, ultrasonically nebulised distilled water,3 4and both the early and late responses to allergen. 5 The role of endogenous prostaglandins and thromboxane in asthma is less clear and has been probed with non-steroidal antiinflammatory drugs (NSAIDs) which inhibit their production by the cyclooxygenase pathway and with thromboxane receptor antagonists.6 Ingestion and inhalation of NSAIDs cause bronchoconstriction in a small proportion of patients with asthma and, very occasionally, bronchodilatation. In most patients, however, they cause little change in resting lung function, suggesting that endogenous prostaglandins may not be important. Other studies, however, suggest that both constrictor and protective prostaglandins are active in asthmatic airways. Inhaled lysine aspirin, indomethacin, and sodium salicylate inhibit the late response to allergen7-' and lysine aspirin and indomethacin protect against ultrasonically nebulised distilled water induced bronchoconstriction,"' suggesting that bronchoconstrictor tone in these circumstances is prostaglandin dependent. Inhibitory prostaglandins such as PGE2 appear to have a role in the development of refractoriness following indirectly acting challenges since this is inhibited by NSAIDs, and there is some evidence to suggest that they mediate the effects of frusemide although this has been less consistent. The protective effect of frusemide on bronchoconstriction following exercise was attenuated by oral indomethacin in one study" but augmented by inhaled lysine aspirin'2 and oral flurbiprofen'3 in others. Thus, there is evidence that both constrictor and protective prostaglandins play a part in determining airway calibre under certain circumstances, although there are many unexplained inconsistencies in the literature.
One problem when comparing studies on the effects of NSAIDs in asthma is the considerable variation in the drugs given, doses, routes of administration, osmolarity and pH of the inhaled solutions, and the bronchial challenge tests used to assess the response. NSAIDs are a non-homogeneous group of chemical compounds with varying effects on the two cyclooxygenase isoenzymes currently identified, COX-1 and COX-2." Discrepancies in the literature may therefore be due to differences in the drugs, the methodologies used, or to differences in osmolarity or pH of the inhaled solutions.
The bronchoconstriction caused by sodium metabisulphite is thought to act via release of sulphur dioxide (SO2)"' and activation of neural pathways. '6 7 In contrast, the bronchoconstriction caused by inhalation of adenosine and its related nucleotide, adenosine 5'-monophosphate (AMP), appears to be largely due to histamine release from primed airway mast cells; '8 19 selective HI-receptor antagonists such as terfenadine inhibit the response to AMP20 in patients with asthma but not the response to sodium metabisulphite.2' The effect of inhaled NSAIDs on the airway response to inhaled MBS and AMP has not been studied. We have therefore compared the protective effect of three nebulised NSAIDs against inhaled MBS and AMP induced bronchoconstriction in asthmatic subjects who were not sensitive to aspirin to see whether contractile prostaglandins were involved in these challenges. We also assessed whether the osmolarity or pH of the inhaled solutions were related to any protective effect.
Methods

SUBJECTS
Fifteen non-smoking subjects (one woman) aged 21-51 years with mild asthma and no history of aspirin induced asthma were studied. Twelve were atopic (two or more positive skin prick tests to common allergens). All had asthma that was well controlled, a forced expiratory volume in one second (FEVy) greater than 70% predicted, and no evidence of bronchoconstriction in response to inhaled lysine aspirin in the laboratory (see below). All were taking an inhaled P2 agonist as required, six were taking inhaled beclomethasone (100-200 ztg per day), and one took oral loratadine as required for rhinitis. Inhaled f agonists were withheld for at least 10 hours and oral loratadine for at least 48 hours before each challenge. Subjects were asked to use only paracetamol for pain relief if required during the study period. The study was approved by the City Hospital ethics committee and all subjects gave written informed consent.
MATERIALS
The drugs and chemicals used in the study included lysine aspirin (Laboratoires Synthelabo, Paris, France), indomethacin meglumine (Liometacen, Chiesi Farmaceutici, Parma, Italy), sodium salicylate (E Merck, UK), saline = 0.9% (wt/vol) sodium chloride (Steripak Ltd, UK), 30% sodium chloride (Martindale Pharmaceuticals Ltd, Essex, UK), sodium metabisulphite (MBS) (Thornton Boss Ltd, UK), and adenosine 5'-monophosphate (AMP) (Sigma, Poole, Dorset, UK).
Forced expiratory volume in one second (FEVy) was measured with a dry wedge spirometer (Vitalograph, Buckingham, UK) and the higher of two successive readings within 100 ml was recorded. Sodium metabisulphite and adenosine 5'-monophosphate were dissolved freshly in saline to produce a doubling concentration range of 0.6-160 mg/ml for sodium metabisulphite and 3.12-200 mg/ml for adenosine 5'-monophosphate. Solutions were delivered by a nebuliser attached to a breath actuated dosimeter (Mefar, Brescia, Italy) at a nebulisation time of one second, pause time six seconds, pressure 22 lb/m (152 kPa), output 10.3 jl and 12.8 ,ul per puff for MBS and AMP, respectively. Normal saline was inhaled initially with the subjects inspiring slowly through the mouthpiece from functional residual capacity to total lung capacity over three seconds after the nebuliser was triggered and then breath holding for three seconds. FEV PD20 AMP was significantly higher after L-aspirin and indomethacin (fig 1) . When When the two subjects with three and four censored values were excluded the PD20 MBS values increased to 1.49, 0.84, and 0.79 doubling doses after L-aspirin, indomethacin, and sodium salicylate, respectively, the increase for indomethacin being then statistically significant (p = 0.05) and that for sodium salicylate being almost significant (p < 0.1). The changes to the PD20 AMP values after the subjects with censored values were excluded were minor and did not alter the statistical significance of the findings. Study 2: Osmolarity study All four solutions were well tolerated. The pH ranged from 5.8 (0.9% saline) to 8.2 (indomethacin with 9.5% saline) and the osmolarity from 292 (0.9% saline) to 3005 mOsm/kg (9.5% saline with indomethacin) (table 1). The mean baseline FEV, did not differ significantly between the four study days.
There was a small increase from baseline in FEV, following inhalation of normal saline (0.4%) and a small decrease following the other three solutions (range 1.8-5.7%) causing a difference between the four solutions which was statistically significant at two minutes after inhalation (p = 0.05) but not at five, 10, or 20 minutes.
There was a significant difference in MBS PD20 between the three hyperosmolar solutions (p < 0.05). When compared with the PD20 values following 0.9% saline, MBS PD20 increased significantly by 1.1 doubling dose with indomethacin dissolved in 9.5% saline (95% CI 0.2 to 2.0). The 3% and 10% saline solutions had little effect, altering MBS PD20 by 0.09 (95% CI -0.83 to 0.1) and 0.04 (95% CI -0.88 to 0.95) doubling doses, respectively (fig 2) . No significant difference in mean PD20 MBS values after saline was seen in the 10 patients who took part in studies 1 and 2 (geometric mean 4.9 [tmol and 7.5 jmol, respectively) or in the mean difference in PD20 values relative to saline after indomethacin alone in study 1 (0.93 doubling doses) and indomethacin with 9.5% saline in study 2 (1.1 doubling doses).
Discussion
We have compared the effects of L-aspirin, indomethacin, and sodium salicylate against two bronchoconstrictor challenges with different modes of action in patients with mild 10% saline asthma who were not aspirin sensitive. Most patients with asthma show bronchial hyper-4BS after responsiveness to a large number of stimuli. 30 It is feasible that AMP induced histamine released from mast cells may produce some of its bronchoconstrictor effect by releasing contractile cyclooxygenase products. Thus, COX inhibitors could attenuate AMP induced bronchoconstriction by this mechanism.
If the effect of aspirin and indomethacin is due to COX inhibition, their relative effects on MBS and AMP challenges should reflect their relative potencies as COX inhibitors. Cyclooxygenase exists as two isozymes, COX-1 and COX-2, COX-1 being a constitutive enzyme involved in cellular "housekeeping" functions3' whereas COX-2 is an inducible enzyme which is increased in the presence of inflammation32 33 and is responsible for the production of proinflammatory prostaglandins. When the relative potency of aspirin and indomethacin in inhibiting cyclooxygenase has been studied in broken cell, purified enzymes and intact cell preparations both drugs have been more potent inhibitors of COX-1 than COX-2, although the ratio of COX-1 to COX-2 inhibition has differed depending on the preparation studied.34 It is difficult therefore to predict the relative potency of aspirin and indomethacin in inhibiting the two COX enzymes in the airways other than to say that both drugs are likely to be more selective for COX-1.
If the protective effect of NSAIDs in asthma is due to COX-2 inhibition, larger doses would be needed and this is more likely to be achieved by inhalation. Inhaled indomethacin (50 mg) with 9.5% saline protected against MBS challenge and the magnitude of this effect (1. 1 doubling doses) was similar to that seen in study 1 with the same dose of indomethacin in 0.9% saline in the same subjects (0.9 doubling doses). The 3% and 10% saline solutions had no effect. The osmolarity of the solutions does not therefore appear to be an important determinant of the protective effect of indomethacin. Hyperosmolar saline induced bronchoconstriction has been shown to cause refractoriness40 but whether cross refractoriness occurs to affect other bronchial provocation challenges has not been studied. The lack of effect of hyperosmolar saline on subsequent challenge by MBS in our study may be because the hyperosmolar solution caused minor bronchoconstriction only. The two solutions causing most inhibition were the most acidic (L-aspirin) and the most alkaline (indomethacin), which suggests that pH was not a major determinant of the protection seen.
Thus, inhaled L-aspirin and indomethacin have broadly similar effects against MBS and AMP induced bronchoconstriction in the doses given, although the effect of indomethacin on MBS was not quite statistically significant. The osmolarity and pH of the solutions did not appear to be important determinants of the response. The effect of L-aspirin and indomethacin is likely to be due to cyclooxygenase inhibition which reduces the production of contractile prostaglandins during MBS and AMP challenge.
